Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes
This study aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes. The irbesartan PBPK model was established using the PK-Sim® software. Our previously reported pharmacogenomic data for irbesartan was leveraged in the development of the PBPK model and collected clinical pharmacokinetic data for irbesartan was used for the validation of the model. Physicochemical and ADME properties of irbesartan were obtained from previously reported data, predicted by the modeling software, or optimized to fit the observed plasma concentration-...
Source: Archives of Pharmacal Research - December 8, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Source Type: research
Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes
This study aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes. The irbesartan PBPK model was established using the PK-Sim® software. Our previously reported pharmacogenomic data for irbesartan was leveraged in the development of the PBPK model and collected clinical pharmacokinetic data for irbesartan was used for the validation of the model. Physicochemical and ADME properties of irbesartan were obtained from previously reported data, predicted by the modeling software, or optimized to fit the observed plasma concentration-...
Source: Archives of Pharmacal Research - December 8, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Source Type: research
Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes
This study aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes. The irbesartan PBPK model was established using the PK-Sim® software. Our previously reported pharmacogenomic data for irbesartan was leveraged in the development of the PBPK model and collected clinical pharmacokinetic data for irbesartan was used for the validation of the model. Physicochemical and ADME properties of irbesartan were obtained from previously reported data, predicted by the modeling software, or optimized to fit the observed plasma concentration-...
Source: Archives of Pharmacal Research - December 8, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Source Type: research
Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes
This study aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes. The irbesartan PBPK model was established using the PK-Sim® software. Our previously reported pharmacogenomic data for irbesartan was leveraged in the development of the PBPK model and collected clinical pharmacokinetic data for irbesartan was used for the validation of the model. Physicochemical and ADME properties of irbesartan were obtained from previously reported data, predicted by the modeling software, or optimized to fit the observed plasma concentration-...
Source: Archives of Pharmacal Research - December 8, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Source Type: research
Targeting dysregulated lipid metabolism in the tumor microenvironment
Arch Pharm Res. 2023 Dec 7. doi: 10.1007/s12272-023-01473-y. Online ahead of print.ABSTRACTThe reprogramming of lipid metabolism and its association with oncogenic signaling pathways within the tumor microenvironment (TME) have emerged as significant hallmarks of cancer. Lipid metabolism is defined as a complex set of molecular processes including lipid uptake, synthesis, transport, and degradation. The dysregulation of lipid metabolism is affected by enzymes and signaling molecules directly or indirectly involved in the lipid metabolic process. Regulation of lipid metabolizing enzymes has been shown to modulate cancer dev...
Source: Archives of Pharmacal Research - December 7, 2023 Category: Drugs & Pharmacology Authors: Do-Hee Kim Na-Young Song Hyungshin Yim Source Type: research
Phytochemistry and pharmacology of plants in the genus Chaenomeles
The objective of this review is to provide a comprehensive and up-to-date summary of the available information on the genus Chaenomeles to serve as a valuable reference for further investigations.PMID:38062238 | DOI:10.1007/s12272-023-01475-w (Source: Archives of Pharmacal Research)
Source: Archives of Pharmacal Research - December 7, 2023 Category: Drugs & Pharmacology Authors: Ruoling Xu Mengting Kuang Ning Li Source Type: research
Targeting dysregulated lipid metabolism in the tumor microenvironment
Arch Pharm Res. 2023 Dec 7. doi: 10.1007/s12272-023-01473-y. Online ahead of print.ABSTRACTThe reprogramming of lipid metabolism and its association with oncogenic signaling pathways within the tumor microenvironment (TME) have emerged as significant hallmarks of cancer. Lipid metabolism is defined as a complex set of molecular processes including lipid uptake, synthesis, transport, and degradation. The dysregulation of lipid metabolism is affected by enzymes and signaling molecules directly or indirectly involved in the lipid metabolic process. Regulation of lipid metabolizing enzymes has been shown to modulate cancer dev...
Source: Archives of Pharmacal Research - December 7, 2023 Category: Drugs & Pharmacology Authors: Do-Hee Kim Na-Young Song Hyungshin Yim Source Type: research
Role of monocarboxylate transporter I/lactate dehydrogenase B-mediated lactate recycling in tamoxifen-resistant breast cancer cells
Arch Pharm Res. 2023 Dec 4. doi: 10.1007/s12272-023-01474-x. Online ahead of print.ABSTRACTAlthough tamoxifen (TAM) is widely used in patients with estrogen receptor-positive breast cancer, the development of tamoxifen resistance is common. The previous finding suggests that the development of tamoxifen resistance is driven by epiregulin or hypoxia-inducible factor-1α-dependent glycolysis activation. Nonetheless, the mechanisms responsible for cancer cell survival and growth in a lactic acid-rich environment remain elusive. We found that the growth and survival of tamoxifen-resistant MCF-7 cells (TAMR-MCF-7) depend on gly...
Source: Archives of Pharmacal Research - December 4, 2023 Category: Drugs & Pharmacology Authors: Min Chang Choi Sang Kyum Kim Young Jae Choi Yong June Choi Suntae Kim Kyung Hwan Jegal Sung Chul Lim Keon Wook Kang Source Type: research
Role of monocarboxylate transporter I/lactate dehydrogenase B-mediated lactate recycling in tamoxifen-resistant breast cancer cells
Arch Pharm Res. 2023 Dec 4. doi: 10.1007/s12272-023-01474-x. Online ahead of print.ABSTRACTAlthough tamoxifen (TAM) is widely used in patients with estrogen receptor-positive breast cancer, the development of tamoxifen resistance is common. The previous finding suggests that the development of tamoxifen resistance is driven by epiregulin or hypoxia-inducible factor-1α-dependent glycolysis activation. Nonetheless, the mechanisms responsible for cancer cell survival and growth in a lactic acid-rich environment remain elusive. We found that the growth and survival of tamoxifen-resistant MCF-7 cells (TAMR-MCF-7) depend on gly...
Source: Archives of Pharmacal Research - December 4, 2023 Category: Drugs & Pharmacology Authors: Min Chang Choi Sang Kyum Kim Young Jae Choi Yong June Choi Suntae Kim Kyung Hwan Jegal Sung Chul Lim Keon Wook Kang Source Type: research
Role of monocarboxylate transporter I/lactate dehydrogenase B-mediated lactate recycling in tamoxifen-resistant breast cancer cells
Arch Pharm Res. 2023 Dec 4. doi: 10.1007/s12272-023-01474-x. Online ahead of print.ABSTRACTAlthough tamoxifen (TAM) is widely used in patients with estrogen receptor-positive breast cancer, the development of tamoxifen resistance is common. The previous finding suggests that the development of tamoxifen resistance is driven by epiregulin or hypoxia-inducible factor-1α-dependent glycolysis activation. Nonetheless, the mechanisms responsible for cancer cell survival and growth in a lactic acid-rich environment remain elusive. We found that the growth and survival of tamoxifen-resistant MCF-7 cells (TAMR-MCF-7) depend on gly...
Source: Archives of Pharmacal Research - December 4, 2023 Category: Drugs & Pharmacology Authors: Min Chang Choi Sang Kyum Kim Young Jae Choi Yong June Choi Suntae Kim Kyung Hwan Jegal Sung Chul Lim Keon Wook Kang Source Type: research
Selumetinib overcomes gefitinib primary and acquired resistance by regulating MIG6/STAT3 in NSCLC
Arch Pharm Res. 2023 Nov 30. doi: 10.1007/s12272-023-01471-0. Online ahead of print.ABSTRACTGefitinib, as the first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has achieved great advances in the treatment of non-small cell lung cancer (NSCLC), but drug resistance will inevitably occur. Therefore, exploring the resistance mechanism of gefitinib and developing new combination treatment strategies are of great importance. In our study, the results showed that selumetinib (AZD6244) synergistically inhibited the proliferation of NSCLC with gefitinib. Selumetinib also enhanced gefitinib-indu...
Source: Archives of Pharmacal Research - November 30, 2023 Category: Drugs & Pharmacology Authors: Xiaoping Song Lina Wang Wei Tang Luyao Yuan Qingchao Liu Jing Li Daidi Fan Source Type: research
Selumetinib overcomes gefitinib primary and acquired resistance by regulating MIG6/STAT3 in NSCLC
Arch Pharm Res. 2023 Nov 30. doi: 10.1007/s12272-023-01471-0. Online ahead of print.ABSTRACTGefitinib, as the first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has achieved great advances in the treatment of non-small cell lung cancer (NSCLC), but drug resistance will inevitably occur. Therefore, exploring the resistance mechanism of gefitinib and developing new combination treatment strategies are of great importance. In our study, the results showed that selumetinib (AZD6244) synergistically inhibited the proliferation of NSCLC with gefitinib. Selumetinib also enhanced gefitinib-indu...
Source: Archives of Pharmacal Research - November 30, 2023 Category: Drugs & Pharmacology Authors: Xiaoping Song Lina Wang Wei Tang Luyao Yuan Qingchao Liu Jing Li Daidi Fan Source Type: research
Selumetinib overcomes gefitinib primary and acquired resistance by regulating MIG6/STAT3 in NSCLC
Arch Pharm Res. 2023 Nov 30. doi: 10.1007/s12272-023-01471-0. Online ahead of print.ABSTRACTGefitinib, as the first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has achieved great advances in the treatment of non-small cell lung cancer (NSCLC), but drug resistance will inevitably occur. Therefore, exploring the resistance mechanism of gefitinib and developing new combination treatment strategies are of great importance. In our study, the results showed that selumetinib (AZD6244) synergistically inhibited the proliferation of NSCLC with gefitinib. Selumetinib also enhanced gefitinib-indu...
Source: Archives of Pharmacal Research - November 30, 2023 Category: Drugs & Pharmacology Authors: Xiaoping Song Lina Wang Wei Tang Luyao Yuan Qingchao Liu Jing Li Daidi Fan Source Type: research
Selumetinib overcomes gefitinib primary and acquired resistance by regulating MIG6/STAT3 in NSCLC
Arch Pharm Res. 2023 Nov 30. doi: 10.1007/s12272-023-01471-0. Online ahead of print.ABSTRACTGefitinib, as the first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has achieved great advances in the treatment of non-small cell lung cancer (NSCLC), but drug resistance will inevitably occur. Therefore, exploring the resistance mechanism of gefitinib and developing new combination treatment strategies are of great importance. In our study, the results showed that selumetinib (AZD6244) synergistically inhibited the proliferation of NSCLC with gefitinib. Selumetinib also enhanced gefitinib-indu...
Source: Archives of Pharmacal Research - November 30, 2023 Category: Drugs & Pharmacology Authors: Xiaoping Song Lina Wang Wei Tang Luyao Yuan Qingchao Liu Jing Li Daidi Fan Source Type: research
Human milk oligosaccharides 3'-sialyllactose and 6'-sialyllactose attenuate LPS-induced lung injury by inhibiting STAT1 and NF- κB signaling pathways
Arch Pharm Res. 2023 Nov 9. doi: 10.1007/s12272-023-01470-1. Online ahead of print.ABSTRACTAcute lung injury (ALI) is the leading cause of respiratory diseases induced by uncontrolled inflammation and cell death. Lipopolysaccharide (LPS) is a major trigger of ALI in the progression through macrophage differentiation and the accelerated release of pro-inflammatory cytokines. The present study aimed to investigate the protective effects of human milk oligosaccharides, specifically 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), on LPS-induced ALI and elucidate their underlying signaling pathways. The inhibitory effect...
Source: Archives of Pharmacal Research - November 8, 2023 Category: Drugs & Pharmacology Authors: Yujin Jin Hyesu Jeon Thuy Le Lam Nguyen Lila Kim Kyung-Sun Heo Source Type: research
